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The relative risk (95% CrI) for CGI-I response (active ver-
sus placebo) was 2.56 (2.21, 2.91) for LDX, 2.13 (1.70, 
2.54) for MPH extended release, 1.94 (1.59, 2.29) for GXR, 
1.77 (1.31, 2.26) for ATX, and 1.62 (1.05, 2.17) for MPH 
immediate release. Among non-stimulant pharmacothera-
pies, GXR was more effective than ATX when comparing 
ADHD-RS-IV total score change (with a posterior proba-
bility of 93.91%) and CGI-I response (posterior probability 
76.13%). This study found that LDX had greater efficacy 
than GXR, ATX, and MPH in the treatment of children and 
adolescents with ADHD. GXR had a high posterior prob-
ability of being more efficacious than ATX, although their 
CrIs overlapped.
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Background
The current UK National Institute for Health and Care 
Excellence (NICE) guidelines for attention-deficit/hyperac-
tivity disorder (ADHD) recommend medication for patients 
with severe impairment or for those patients with moder-
ate impairment who have refused non-drug treatments or 
whose symptoms have not responded to other, non-drug 
interventions [1]. Monotherapy with stimulants, including 
amphetamines and methylphenidate (MPH), is the main-
stay of pharmacologic treatment for ADHD in children and 
adolescents; however, about 20–35% of patients are refrac-
tory or intolerant to stimulants [2–5]. In these cases, alter-
native options include non-stimulants and behavioral thera-
pies. These treatments may be in the form of monotherapy 
or, in case of refractoriness or intolerance to monotherapy, 
Abstract This study compared the clinical efficacy and 
safety of attention-deficit/hyperactivity disorder (ADHD) 
pharmacotherapy in children and adolescents 6–17 years 
of age. A systematic literature review was conducted to 
identify randomized controlled trials (RCTs) of pharmaco-
logic monotherapies among children and adolescents with 
ADHD. A Bayesian network meta-analysis was conducted 
to compare change in symptoms using the ADHD Rating 
Scale Version IV (ADHD-RS-IV), Clinical Global Impres-
sion–Improvement (CGI-I) response, all-cause discontinu-
ation, and adverse event-related discontinuation. Thirty-
six RCTs were included in the analysis. The mean (95% 
credible interval [CrI]) ADHD-RS-IV total score change 
from baseline (active minus placebo) was −14.98 (−17.14, 
−12.80) for lisdexamfetamine dimesylate (LDX), −9.33 
(−11.63, −7.04) for methylphenidate (MPH) extended 
release, −8.68 (−10.63, −6.72) for guanfacine extended 
release (GXR), and −6.88 (−8.22, −5.49) for atomoxetine 
(ATX); data were unavailable for MPH immediate release. 
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adjunctive therapy (e.g., add-on therapy) to existing stimu-
lants to help improve symptoms that cannot be controlled 
by stimulants alone.
European guidelines for the management of ADHD in 
children and adolescents [6] include monotherapy with 
stimulants, such as dexamphetamine (d-AMPH), lisdexa-
mfetamine dimesylate (LDX), and MPH, either immedi-
ate release (IR) or extended release (ER)/osmotic-release 
oral system (OROS). For those children and adolescents 
refractory or intolerant to stimulants, alternative options 
include non-stimulants, such as atomoxetine (ATX), clo-
nidine immediate release (CIR), and guanfacine immedi-
ate release (GIR). The NICE guidelines [1] recommend 
ATX and MPH for the management of ADHD in children 
and adolescents aged 6–17 years. Guanfacine extended 
release (GXR) is a non-stimulant approved for both mono-
therapy and adjunctive therapy in children and adolescents 
(6–17 years) in the USA and Canada. In addition, GXR 
was approved by the European Medicines Agency (EMA) 
for children and adolescents (6–17 years) in September 
2015. The availability of treatments with different mecha-
nisms of action provides opportunities for additional treat-
ment strategies when patients do not adequately respond to 
prior therapies.
The objective of this study was to compare the clinical 
efficacy and safety of ADHD pharmacotherapies in chil-
dren and adolescents aged 6–17 years. A number of rand-
omized clinical trials have compared the efficacy and safety 
of these pharmacotherapies with each other or with placebo 
in children and adolescents. A recently published study 
conducted a meta-analysis incorporating published data 
from randomized controlled trials (RCTs) containing GXR 
and placebo [7]. However, the present study has a broader 
scope, performing a mixed treatment comparison (MTC) of 
EMA-approved pharmacotherapies and GXR in a network 
meta-analysis framework. It incorporates both direct and 
indirect evidence, from a wider range of sources.
Methods
Search strategy and inclusion/exclusion criteria
The review included RCTs with publications reporting the 
safety and efficacy of pharmacotherapies for the treatment 
of ADHD in children and adolescents. The following elec-
tronic databases were included in the search: MEDLINE; 
EMBASE; PsychINFO; Cochrane Central Register of 
Controlled Trials; CINAHL; and Science Citation Index. 
The last 4 years of the following conferences were also 
included: European Congress of Psychiatry (European Psy-
chiatric Association; EPA); and European Society of Child 
and Adolescent Psychiatry (ESCAP) Congress. Abstracts 
from the American Academy of Child and Adolescent Psy-
chiatry (AACAP) annual meeting were included for 2012–
2014; 2015 abstracts could not be accessed.
The search included articles indexed through May 2016. 
No time restriction was applied to database searches of 
the drugs. Detailed search criteria are available in Online 
Resource 1.
Inclusion and exclusion criteria were designed to 
broadly identify available information on treatments for 
ADHD in children and adolescents. Studies were eligible if 
they satisfied the following conditions:
•	 A placebo or active comparator RCT.
•	 Included children or adolescents aged 6–17 years with 
ADHD.
•	 Interventions included monotherapy with at least one 
drug of interest (i.e., d-AMPH, ATX, CIR, GIR, GXR, 
LDX, MPH-IR, or MPH-ER/OROS).
•	 Reported efficacy or safety outcomes after a treatment 
duration of ≤16 weeks.
•	 Included ˃25 patients.
Trials were excluded if all patients had a comorbid con-
dition in addition to ADHD. In addition, as the comparison 
with non-stimulants was a novel element of this study, trials 
were excluded if they could not be connected to GXR and 
ATX in an evidence network via a chain of common com-
parators. As a consequence, only parallel-arm studies were 
included—crossover studies were excluded if they did not 
report results for the parallel phase (just prior to crossover).
RCTs identified in the initial search were screened for 
consistency with the inclusion and exclusion criteria. 
Data extraction was then performed on the selected stud-
ies. Means and standard errors for continuous outcomes 
and rates for dichotomous outcomes were extracted from 
the publications for the included trials. In addition, patient 
baseline characteristics and characteristics of the rand-
omized dosing arms, including sample size, age, sex, race, 
baseline ADHD Rating Scale Version IV (ADHD-RS-IV) 
total score, and comorbidities, were extracted.
Outcomes
The following efficacy outcomes were assessed for possi-
ble inclusion in meta-analyses:
•	 Change from baseline-to-study endpoint in ADHD-RS-
IV total score. ADHD-RS-IV is a symptom measure-
ment scale where the total score ranges from 0 to 54, 
with a higher score indicating more severe ADHD [8].
•	 Achievement of Clinical Global Impression–Improve-
ment (CGI-I) response. CGI-I measures overall 
improvement in ADHD. CGI-I response was defined as 
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a CGI-I score of 1 (very much improved) or 2 (much 
improved) [9].
•	 Clinical Global Impression–Severity (CGI-S). CGI-S 
measures severity of ADHD on a scale from 1 to 7 [9].
•	 Conners’ Parent Rating Scales (CPRSs). The CPRSs 
consist of items scored by parents on a 4-point scale. 
The short form comprises 27 items, while the long form 
comprises 80 items [10].
•	 Swanson, Nolan, and Pelham Scale (SNAP-IV). SNAP-
IV is a 90-item rating scale, with each item rated on a 
4-point scale [11].
Safety outcomes considered were all-cause discontinua-
tion and discontinuation due to adverse events (AEs). The 
feasibility of forming a connected network for each out-
come was assessed based on data availability in the system-
atic literature review results. Different outcomes were not 
combined in any way in the analyses.
Quality assessment
The quality of studies was assessed according to the fol-
lowing criteria from the NICE specification for manufac-
turer/sponsor submission of evidence in single technology 
appraisals [12]:
•	 Randomization was carried out appropriately.
•	 Concealment of treatment allocation was adequate.
•	 Groups were similar at the outset of the study in terms 
of prognostic factors.
•	 Care providers, participants, and outcome assessors 
were blind to treatment allocation.
•	 Study was assessed for any unexpected imbalances in 
dropouts between groups.
•	 Study was assessed for evidence suggestive that the 
authors measured more outcomes than they reported.
•	 Study was assessed for whether the analysis included 
an intention-to-treat analysis, whether this method was 
appropriate, and, if so, and whether appropriate meth-
ods were used to account for missing data.
Two reviewers independently rated the screening, data 
extraction, and quality of each study, and discrepancies 
between the reviewers were resolved through consultation 
with a third reviewer.
Core and sensitivity mixed treatment comparisons
Each outcome was assessed in a core analysis and a set of 
sensitivity analyses. The specific analyses performed were 
dependent on the data available from the systematic litera-
ture review.
Core analyses
The core analysis for each identified outcome had the fol-
lowing characteristics:
•	 A random-effects model for the effect of each treat-
ment compared with placebo, with one treatment arm 
per drug, and including study-level random effects to 
account for heterogeneity in the outcome.
•	 Adjusted for baseline covariates to the extent that data 
were available.
•	 Excluded short-term studies (≤3 weeks).
When conducting the MTC, all doses of a particular 
drug were treated as the same. For example, study arms 
receiving GXR at 2, 3, or 4 mg/day would all be considered 
as the same treatment, GXR.
Sensitivity analyses
Sensitivity analyses were performed for each outcome to 
assess the robustness of the findings to variations in the 
methodology. Adjustments for different sets of baseline 
covariates were considered. Variations in the statistical 
method used to account for outcome heterogeneity (fixed 
versus random effects) were explored. In addition, short-
term studies (duration ≤3 weeks) were also considered 
for inclusion in a sensitivity analysis if this substantially 
increased the number of trials that could be included in the 
analysis.
Statistical methodology
Indirect comparison methods can be used when there is 
interest in comparing treatments for which no head-to-head 
trials exist. MTCs are a special case that allow the simulta-
neous estimation of the effects of multiple treatments and 
can incorporate both indirect and direct comparisons [13]. 
The MTC methodology was chosen for the statistical anal-
ysis in order to simultaneously evaluate the effects of these 
treatments and because there were both indirect and direct 
comparisons between the treatments of interest. In accord-
ance with the most recent guidance from the NICE Deci-
sion Support Unit technical support documents and ISPOR 
good practices for indirect comparison, a Bayesian network 
meta-analysis approach to MTC was used [14, 15]. Bayes-
ian network meta-analysis models for MTCs were fit to 
estimate the effect of each treatment on each feasible effi-
cacy or safety outcome. The analyses were implemented 
using the statistical software R (https://cran.r-project.org). 
Gibbs sampling for Bayesian inference was performed 
using JAGS (http://mcmc-jags.sourceforge.net).
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An estimate of treatment effect comparing each treat-
ment with a common comparator (i.e., placebo) was gen-
erated using the network meta-analysis. For continuous 
outcomes, a normal likelihood model with linear link was 
employed, and the difference from placebo in mean base-
line-to-endpoint change in score was reported. For cat-
egorical outcomes, a binomial likelihood model with logit 
link was employed, and relative rates were estimated using 
a pooled placebo rate. The placebo rate was computed 
by pooling all the placebo arms in the data, weighted by 
sample size. Specifically, this was done by first generating 
placebo-arm rates using their sampling distributions, and 
incorporating the placebo-arm risk into the Bayesian model 
in accordance with NICE guidelines.
The core analyses incorporated a meta-regression adjust-
ment for differences in baseline characteristics among the 
included studies (Online Resource 2). The baseline char-
acteristics included in the meta-regression were those that 
were consistently measured and available in the included 
trials in each analysis. Additional meta-regression adjust-
ments for covariates were included as sensitivity analyses 
where possible, including models with no meta-regression 
adjustment, as well as models that included additional 
covariates in the adjustment at the cost of a reduction in the 
number of trials that could be included in the analysis.
Prior information about the treatment effects, which was 
needed for the Bayesian analyses, was chosen to be non-
informative in order to avoid a preference for any specific 
values of the treatment effects and to avoid biasing the 
parameter estimates. Markov chain Monte Carlo methods 
were used to obtain posterior distributions in the Bayesian 
analysis. A Gibbs sampler with 50,000 burn-in iterations 
and an additional 50,000 iterations was implemented to 
generate the posterior distributions for the treatment effects 
for each outcome of interest. Convergence of the Gibbs 
sampler was assessed using the Geweke method and Hei-
delberg–Welch stationarity and half-width tests [16–19]. 
The uncertainty of the estimates of treatment effects were 
summarized using 95% Bayesian credible intervals (CrIs) 
based on the 2.5 and 97.5 percentiles of the posterior dis-
tribution of the treatment effects. Non-overlap of 95% CrIs 
was interpreted as strong evidence that the treatment effects 
differ. In addition, the probability that each drug had the 
highest efficacy among all treatments was estimated based 
on posterior distributions. GXR was also compared individ-
ually with each of the other drugs, and the efficacy and dis-
continuation probability rates in comparison with each of 
the other drugs were reported. In addition, posterior density 
plots of the posterior distributions of the treatment effects 
were produced for each of the analyses.
Heterogeneity in the evidence network for the efficacy 
analyses was assessed using methods suggested in the 
NICE guidelines on evidence synthesis. Both fixed- and 
random-effects models were fitted to account for different 
assumptions regarding heterogeneity of treatment effects. 
Fixed-effects models assume a common treatment effect 
for a given treatment across studies; random-effects mod-
els assume that the treatment effects are not necessarily 
the same but are exchangeable in the sense that, while the 
actual treatment effect may vary across trials by chance, 
there are no structural differences between the trials. As a 
primary assessment of heterogeneity, the deviance informa-
tion criterion (DIC) was compared between the fixed- and 
random-effects models. In addition, based on NICE guide-
lines [20], outcome heterogeneity was assessed (without 
regard to the meta-regression adjustments used in the anal-
ysis) using I2 and Cochran’s Q measures in trials compar-
ing all pairs of drugs that were compared in two or more 
trials. Use of these three heterogeneity measures is consist-




A total of 10,442 records, including database searches and 
conferences satisfied the initial search criteria. After an 
assessment of data availability following screening, three 
outcomes (CGI-S, CPRS, and SNAP-IV) were dropped 
from the analyses due to the absence of sufficiently many 
studies reporting these outcomes to form connected net-
works to compare these outcomes through common com-
parators. Sufficient data were available to form a net-
work of treatments for the following outcomes: change in 
ADHD-RS-IV total score, CGI-I response, all-cause dis-
continuation, and discontinuation due to AEs. No data on 
MPH-IR were available for change in ADHD-RS-IV total 
score.
Data availability allowed for comparison of GXR, 
LDX, ATX, MPH-ER/MPH-OROS, and MPH-IR. The 
treatments d-AMPH, CIR, and GIR could not be included 
in any of the networks due to insufficient data to popu-
late the network. Not all trials with MPH identified the 
intervention as extended or immediate release. Hence, 
an additional classification step was undertaken whereby 
MPH treatment was classified as MPH-IR if the drug was 
administered more than twice a day, and as MPH-ER oth-
erwise. This classification was further reviewed to deter-
mine whether the classification was reasonable, and the 
impact on the findings was assessed by considering the 
number and size of the studies for which the classification 
was necessary. Of 20 RCTs that included an MPH arm, 
4 articles did not specify whether the MPH formulation 
Eur Child Adolesc Psychiatry 
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was ER or IR. Of these 4 articles, 3 were small (with 
MPH sample sizes of 20 [24], 32 [27], and 90 [59]) and 
one was moderate sized (MPH sample size of 166 [56]). 
Details are provided in Online Resource 2. A sensitivity 
analysis was performed, changing the classification for 
the largest study from MPH-ER to MPH-IR. All MPH-
OROS studies were classified as MPH-ER.
A total of 36 RCTs met the screening criteria and were 
included in the analysis for at least one of the outcomes 
(Fig. 1; Table 1). In total, 20 articles were included in the 
Fig. 1  PRISMA diagram for the efficacy and safety of ADHD treat-
ments for children and adolescents. aExclusions for non-human stud-
ies, not an ADHD population, and studies focusing on adults only 
(i.e., no children or adolescents included). bDid not include treat-
ments of interest (methylphenidate, atomoxetine, dexamphetamine, 
lisdexamfetamine/lisdexamphetamine, clonidine, or guanfacine). 
cPreclinical studies, Phase I studies, prognostic studies, retrospective 
studies, case reports, audio files, commentaries and letters (publica-
tion type), consensus reports, nonsystematic reviews, or titles with-
out corresponding abstracts (title/abstract screening only). dFor title/
abstract screening, studies reporting only pharmacokinetics or bio-
chemical, neuroimaging, or genetic outcomes were excluded. For full 
text screening, studies that did not report at least one of the follow-
ing efficacy measures commonly used in child and adolescent ADHD 
were excluded: ADHD-RS-IV, CGI scales, Conners’ Parent Rating 
Scale, or Swanson, Nolan, and Pelham scale. All studies of clonidine 
IR and guanfacine IR were excluded at this stage because none of the 
efficacy outcomes reported in those studies could be used to form a 
connected network that included guanfacine extended release and ato-
moxetine. eIncluding studies for which the full text is not available for 
open access download or for purchase. fSix short-term studies were 
included in the sensitivity analyses of CGI-I comparison: Wilens 
et al. [21], Kemner et al. [22], Greenhill et al. [23], Pliszka et al. 
[24], Biederman et al. [25], and Findling et al. [26]. Additionally, 
one study not reporting baseline characteristics was included in the 
sensitivity analyses of all-cause discontinuation: Ialongo et al. [27]. 
gWhen full or precise information was not available in the publica-
tion (e.g., results shown in a graph, results for pooled treatment arms, 
standard errors not reported) and the CSR was available, numbers 
were extracted from the CSR. CSRs were used to extract information 
on ADHD-RS-IV mean change and standard errors corresponding 
to Biederman et al. [28, 29] and Sallee et al. [30]. Two studies that 
did not report standard errors for ADHD-RS-IV were excluded. hOne 
publication contained two studies [31]. We considered these to be two 
separate RCTs, and labeled them as Spencer  et al. [31]. However, we 
identified an additional publication of one of these studies, which is 
included in the count of articles. iDue to differences in the outcomes 
reported in the RCTs, a total of 36 distinct RCTs were included in 
the four mixed treatment comparison analyses, although no more than 
32 RCTs reported any one outcome. AACAP American Academy of 
Child and Adolescent Psychiatry, ADHD attention-deficit/hyperactiv-
ity disorder, ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder 
Rating Scale Version IV, CGI-I Clinical Global Impression–Improve-
ment, CSR clinical study report, EPA European Psychiatric Associa-
tion, ESCAP European Society of Child and Adolescent Psychiatry, 
IR immediate release, MTC mixed treatment comparison, RCT rand-
omized controlled trial
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network for ADHD-RS-IV total score change (Fig. 2), 
14 for CGI-I response (Fig. 3), 31 for all-cause discon-



























































































































































































































































































































































































































Fig. 2  Evidence network for ADHD-RS-IV total score change from 
baseline. Methylphenidate immediate release, clonidine immedi-
ate release, and guanfacine immediate release could not be included 
in the network due to lack of data. Trials: Biederman [28]; Bieder-
man [29]; Coghill [33]; Dittmann [35]; Findling [37]; Gau [40]; Her-
vas [41]; Kelsey [42]; Kollins [43]; Martenyi [45]; Michelson [46]; 
Michelson [47]; Montoya [48]; Newcorn [49]; Newcorn [50]; Sallee 
[30]; Spencer [31]; Wang [56]; Wilens [60]. ADHD-RS-IV Attention-
Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atom-
oxetine, GXR guanfacine extended release, LDX lisdexamfetamine 
dimesylate, MPH-OROS/ER methylphenidate extended release/
osmotic-release oral system
Fig. 3  Evidence network for CGI-I response, defined as a CGI-I 
score of 1 or 2. Clonidine immediate release and guanfacine immedi-
ate release could not be included in the network due to lack of data. 
aIndicates short-term studies, which are not included in the core anal-
ysis but are included in sensitivity analysis. Trials: Biederman [25]; 
Biederman [29]; Coghill [33]; Dittmann [35]; Findling [26]; Find-
ling [36]; Findling [37]; Gau [39]; Greenhill [23]; Hervas [41]; Kel-
sey [42]; Kemner [22]; Kollins [43]; Pliszka [24]; Sallee [30]; Steele 
[53]; Wigal [59]; Wilens [21]; Wilens [61]; Wolraich [62]. ATX ato-
moxetine, Clinical Global Impression–Improvement, GXR guanfacine 
extended release, LDX lisdexamfetamine dimesylate, MPH-OROS/ER 
methylphenidate extended release/osmotic-release oral system, MPH-
IR methylphenidate immediate release
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(Fig. 5). All of the trial results were published between 
1994 and 2016. Of the 36 RCTs, 6 trials had GXR arms, 
4 trials had LDX arms, 21 trials had ATX arms, 10 tri-
als had MPH-ER arms, and 6 trials had MPH-IR arms. 
Among these, 1 trial had GXR and ATX arms, 1 trial 
had LDX and ATX arms, 1 trial had LDX and MPH-ER 
arms, 4 trials had ATX and MPH-ER arms, 1 trial had 
ATX and MPH-IR arms, and 3 trials had MPH-ER and 
MPH-IR arms. The same 36 RCTs were also used in the 
majority of sensitivity analyses. In addition, six short-
term studies (duration ≤3 weeks) were included in sen-
sitivity analyses of CGI-I comparison: Biederman et al. 
[25], Findling et al. [26], Greenhill et al. [23], Kemner 
et al. [22], Pliszka et al. [24], and Wilens et al. [21]; one 
study (Ialongo et al. [27]) not reporting baseline percent 
female or age was included in the sensitivity analyses of 
all-cause discontinuation.     
RCT characteristics
All of the studies used the DSM-IV criteria, except for 
the study of Pliszka et al. [24], which used the diagnos-
tic interview schedule for children [63] and the study of 
Ialongo et al. [27], which used the DSM-II criteria. Study 
durations ranged from 3 to 16 weeks for the double-blind 
period. Sample sizes ranged from 16 to 222 subjects 
per arm; the total number of patients ranged from 1987 
for ATX in the AE-related discontinuation analysis to 
230 for MPH-IR in the all-cause discontinuation analy-
sis (Table 2). Mean age at baseline ranged from 8.5 to 
14.6 years and the proportion of females ranged from 9.4 
to 36.1%. The mean baseline ADHD-RS-IV total score 
was available in 22 studies and ranged from 31.5 to 43.5. 
Across the analyses of various outcomes, the average 
dose ranged from 2.87 to 4.30 mg/day for GXR, 44.40 
to 51.52 mg/day for LDX, 17.46 to 47.09 mg/day for 
ATX, 18.00 to 39.03 mg/day for MPH-ER, and 17.35 to 
30.76 mg/day for MPH-IR.
Quality assessment criteria were examined for all 
included studies (Table 3). All of the studies were blinded, 
except for Kemner et al. [22], Steele et al. [53], Gau et al. 
[39], Garg et al. [38], Shang et al. [52], and Su et al. [54], 
which were open-label studies. The method of ADHD-RS-
IV rating was generally consistent across trials. The most 
common scoring method was the ADHD-RS-IV Parent 
Version: Investigator Administered and Scored. All except 
two studies reporting ADHD-RS-IV specified that the 
measure was investigator scored, with most further specify-
ing that the scoring was based on interviews with parents. 
Dittman et al. [35] and Hervas et al. [41] were not specific 
about scoring, but did not indicate that any other scoring 
method was used.
Fig. 4  Evidence network for all-cause discontinuation Clonidine 
immediate release and guanfacine immediate release could not be 
included in the network due to lack of data. aStudy does not report 
baseline age or percent female and thus was not included in the core 
analysis but was included in the sensitivity analyses. Trials: Bieder-
man [28]; Biederman [29]; Block [32]; Coghill [33]; Dittmann [34]; 
Dittmann [35]; Findling [36]; Findling [37]; Garg [38]; Gau [40]; 
Hervas [41]; Ialongo [27]; Kelsey [42]; Kollins [43]; López [44]; 
Martenyi [45]; Montoya [48]; Newcorn [49]; Newcorn [50]; Palumbo 
[51]; Sallee [30]; Shang [52]; Spencer [31]; Steele [53]; Su [54]; 
Takahashi [55]; Wang [56]; Weiss [58]; Wilens [60]; Wilens [61]; 
Wolraich [62]. ATX atomoxetine, GXR guanfacine extended release, 
LDX lisdexamfetamine dimesylate, MPH-ER/OROS methylphenidate 
extended release/osmotic-release oral system, MPH-IR methylpheni-
date immediate release
Fig. 5  Evidence network for discontinuation due to adverse events. 
Clonidine immediate release and guanfacine immediate release could 
not be included in the network due to lack of data. Trials: Biederman 
[28]; Biederman [29]; Block [32]; Coghill [33]; Dittmann [34]; Ditt-
mann [35]; Findling [36]; Findling [37]; Garg [38]; Gau [39]; Hervas 
[41]; Kelsey [42]; Kollins [43]; López [44]; Martenyi [45]; Montoya 
[48]; Newcorn [49]; Newcorn [50]; Palumbo [51]; Sallee [30]; Shang 
[52]; Spencer [31]; Steele [53]; Su [54]; Takahashi [55]; Wang [56]; 
Wehmeier [57]; Weiss [58]; Wigal [59]; Wilens [60]; Wilens [61]; 
Wolraich [62]. ATX atomoxetine; GXR guanfacine extended release, 
LDX lisdexamfetamine dimesylate, MPH-ER/OROS methylphenidate 
extended release/osmotic-release oral system, MPH-IR methylpheni-
date immediate release
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Trial selection and meta‑regression adjustments
Trials meeting the selection criteria were examined to 
determine which specific core and sensitivity analyses were 
feasible (Table 4). Baseline age and percent female were 
consistently measured for all but one study (Ialongo et al. 
[27]) and were available for adjustment via meta-regression 
in the included trials for all outcomes as well as in meta-
regression adjustments in the core analyses. As Ialongo 
et al. [27] was missing baseline age and percent female 
data, it was not included in the core analyses. Baseline 
ADHD-RS-IV score was not reported for one GXR trial 
in the ADHD-RS-IV network and was not reported in a 
substantial number of trials in the CGI-I network. Hence, 
baseline ADHD-RS-IV score was only adjusted for in the 
sensitivity analyses and not in the core analyses. Other 
trial-level patient characteristics (e.g., prior treatment, 
comorbidities) could not be considered due to lack of data 
and inconsistency in definitions across trials. In the CGI-I 
analysis, a substantial number of studies (six) had a dura-
tion of ≤3 weeks; hence, a sensitivity analysis was con-
ducted including these short-term studies.
Analysis of efficacy
ADHD-RS-IV
LDX demonstrated significantly better efficacy than other 
treatments in terms of baseline-to-endpoint ADHD-RS-IV 
symptom total score change in children and adolescents. 
Specifically, the mean ADHD-RS-IV total score decrease 
from baseline relative to placebo was 14.98 (95% CrI 
12.80, 17.14) for LDX, 9.33 (95% CrI 7.04, 11.63) for 
MPH-ER, 8.68 (95% CrI 6.72, 10.63) for GXR, and 6.88 
(95% CrI 5.49, 8.22) for ATX (Table 5). There was separa-
tion in the 95% posterior CrIs of LDX compared with other 
treatments, and LDX had a 99.96% probability of being the 
most efficacious of all pharmacotherapies within the net-
work. Among the non-stimulants, GXR was more effective 
than ATX with respect to ADHD-RS-IV change. Although 
the CrIs for GXR and ATX overlapped, the probability of 
GXR being more effective than ATX was 93.91%. Poste-
rior density plots showed that the distribution of LDX was 
concentrated at a greater reduction in ADHD-RS-IV symp-
tom score relative to the other treatments within the net-
work, and that the profile of GXR visually resembled that 
of MPH-ER. MPH-IR was not included in this network 
because there were no available trials.
In every sensitivity analysis, LDX continued to have 
the highest efficacy, with the probabilities of it being the 
most efficacious treatment ranging from 99.00 to 100.00%. 
There was no overlap with other drugs in the CrIs in any 
of the sensitivities, except for the random-effects model not 
adjusted for baseline covariates, in which there was over-
lap in CrIs between LDX and MPH-ER. In every sensi-
tivity analysis, GXR was more efficacious than ATX, but 
with overlapping CrIs. The probability of GXR having 
greater efficacy than ATX remained high, ranging from 
81.19 to 97.86%. In the sensitivity analysis modifying the 
MPH classification in Wang 2007 [56] from ER to IR, the 
results remained similar to those in the core analyses: the 
ADHD-RS-IV total score decrease from baseline relative to 
placebo was 10.28 (95% CrI 7.67, 12.88) for MPH-ER and 
7.21 (95% CrI 3.30, 11.14) for MPH-IR, and was nearly 
unchanged for LDX, GXR, and ATX.
CGI-I
The best clinical response measured by CGI-I among all 
pharmacotherapies within the network was again observed 
in LDX: point estimates of relative risk (RR) were 2.56 
(95% CrI 2.21, 2.91) for LDX, followed by 2.13 (95% CrI 
1.70, 2.54) for MPH-ER, 1.94 (95% CrI 1.59, 2.29) for 
GXR, 1.77 (95% CrI 1.31, 2.26) for ATX, and 1.62 (95% 
CrI 1.05, 2.17) for MPH-IR (Table 6). The placebo risk was 
0.31 (95% confidence interval [CI] 0.28, 0.34). The proba-
bility of LDX being the most efficacious drug was 96.21%. 
Among the non-stimulants, although the CrIs for GXR and 
Table 2  Sample sizes for the core analyses
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, AE adverse event, ATX atomoxetine, CGI-I Clinical Global 
Impression–Improvement, GXR guanfacine extended release, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate 
release, LDX lisdexamfetamine dimesylate
ADHD-RS-IV total score change CGI-I response All-cause discontinuation AE discontinuation
Placebo 1262 930 1675 1779
ATX 1465 370 1924 1987
GXR 958 894 1130 1130
LDX 673 453 697 697
MPH-ER 491 394 1062 1062
MPH-IR 0 245 230 276
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ATX overlapped, the probability that GXR was more effec-
tive than ATX was 76.13%. Posterior density plots showed 
that the distribution of LDX was concentrated at a greater 
RR of CGI-I response than the other treatments, with rela-
tively little overlap with other distributions.
In every sensitivity analysis for CGI-I response, LDX 
was the most efficacious treatment with probabilities rang-
ing from 74.51 to 99.97%, although the CrIs for LDX 
overlapped with those of at least one other drug in all of 
the sensitivity analyses except for the fixed-effects model 
including short-term studies. MPH-ER was the second 
most efficacious drug in every sensitivity analysis, while 
GXR, ATX, and MPH-IR varied in their rankings. Among 
non-stimulants, GXR was observed to be more effective 
than ATX in every sensitivity analysis, but with overlapping 
CrIs. When adding studies with short-term treatment dura-
tion, the percent response of GXR over ATX increased, in 
terms of the probability of GXR being more effective rela-
tive to ATX. In all of the models, GXR had a high probabil-
ity of being more effective than ATX, ranging from 57.16 
to 98.35% in sensitivity analyses.
Assessment of heterogeneity
Heterogeneity was assessed in the core efficacy analyses. 
In the ADHD-RS-IV network, the DIC for the fixed-effects 
model (229.53) was lower than for the random-effects model 
(239.21). In the CGI-I network, the DIC for the fixed-effects 
model (251.65) was also lower than for the random-effects 
model (256.74). Thus, based on the DIC statistic [20, 64], 
the fixed-effects model fits the data as well or better than the 
random-effects model, indicating low residual heterogeneity 
in the meta-regression adjusted analyses. In the ADHD-RS-
IV network, pairwise assessments of outcome heterogeneity 
based on the I2 and Q-statistics did not detect statistically 
significant heterogeneity in 4 of the 5 pairs for which hetero-
geneity assessment was possible (Table 7). Pairwise hetero-
geneity assessments indicate the presence of heterogeneity 
prior to meta-regression adjustments. An I2 of 0% indicates 
that there is no statistical evidence of heterogeneity; an I2 of 
70% or above suggests considerable heterogeneity may be 
present [64]. A significant Q-statistic, or one which is large 
in relation to degrees of freedom, can imply heterogeneity 
[65]. In the ADHD-RS-IV network, an I2 of 94% (95% CI 
86, 98) and Q-statistic of 34.39 (p < 0.01) was estimated in 
the LDX versus placebo trials. In the CGI-I network, hetero-
geneity assessment was possible in 6 pairwise comparisons 
(Table 7), of which 2 demonstrated statistically significant 
heterogeneity as measured by the Q-statistic: I2 of 94% (95% 
CI not calculated) and Q-statistic of 16.86 (p < 0.01) in the 
LDX versus placebo trials; I2 of 86% (95% CI not calcu-
lated) and Q-statistic of 7.07 (p < 0.01) in the ATX versus 
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heterogeneity in the LDX versus placebo trials for both out-
comes, and in the ATX versus placebo trials for the CGI-I 
score. However, the DIC assessment indicates that there is 
no evidence of residual heterogeneity after accounting for 
the meta-regression adjustments used in the analyses.
Analysis of safety
All-cause discontinuation
RR estimates for all-cause discontinuation were 0.44 (95% 
CrI 0.25, 0.69) for MPH-IR, 0.52 (95% CrI 0.38, 0.69) for 
MPH-ER, 0.66 (95% CrI 0.46, 0.91) for LDX, 0.87 (95% 
CrI 0.66, 1.12) for GXR, and 0.88 (95% CrI 0.71, 1.08) 
for ATX. The placebo risk was 0.28 (95% CI 0.26, 0.30) 
(Table 8). The probability of MPH-IR being least likely to 
be discontinued was 77.23%. Among non-stimulants, the 
probability of GXR being more likely to be discontinued 
than ATX was 49.02%. The 95% CrIs and posterior density 
plots for these point estimates showed considerable overlap 
between treatments.
In all sensitivity analyses, MPH-IR continued to be the 
treatment least likely to be discontinued due to any cause, 
with probabilities ranging from 84.16 to 92.40%. MPH-
IR was followed in all-cause discontinuation by MPH-ER 
and LDX, although CrIs overlapped between all drugs. 
While the core analysis found ATX to be most likely 
drug to be discontinued, followed by GXR, the sensitivity 
analyses found GXR to be the most likely to be discon-
tinued, followed by ATX. The probability of GXR being 
more likely to be discontinued than ATX ranged from 
54.03 to 94.77% in sensitivity analyses. In the sensitiv-
ity analysis modifying the MPH classification in Wang 
2007 [56] from ER to IR, all findings remained nearly 
unchanged relative to those in the core analyses.
Discontinuation due to AEs
RR estimates for AE-related discontinuation were 1.20 
(95% CrI 0.32, 3.06) for MPH-IR, 1.38 (95% CrI 0.60, 
2.68) for MPH-ER, 2.39 (95% CrI 1.26, 4.11) for ATX, 
3.11 (95% CrI 1.20, 6.76) for LDX, and 4.49 (95% CrI 
2.10, 8.81) for GXR. The placebo rate was 0.02 (95% CI 
0.01, 0.02) (Table 9). The probability of MPH-IR being 
the least likely drug to be discontinued was 63.85%. 
Among non-stimulants, the probability of GXR being 
more likely to be discontinued than ATX was 92.26%. 
The 95% CrIs for all treatments overlapped and density 
plots of the posterior samples also showed considerable 
overlap in the distributions for all the treatments. The 
number of discontinuation events for MPH-IR was small 
(9 events); this led to skewed posterior distributions and 
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In all sensitivity analyses, MPH-IR continued to be the 
treatment least likely to be discontinued in terms of AE-
related discontinuation, with probabilities ranging from 
62.90 to 73.18%. MPH-IR was followed in tolerability by 
MPH-ER, ATX, LDX, and GXR in all sensitivity analy-
ses, except for the fixed-effects adjusted model, where 
LDX had a lower RR than ATX; CrIs overlapped between 
all drugs in the sensitivity analyses. The probability of 
GXR being more likely to be discontinued than ATX 
ranged from 90.39 to 96.87% in sensitivity analyses. In 
the sensitivity analysis modifying the MPH classification 
in Wang 2007 [56] from ER to IR, all findings remained 
nearly unchanged relative to those in the core analyses.
Discussion
To our knowledge, this is the first systematic compari-
son of the safety and efficacy of GXR with other phar-
macotherapies available, indicated, or frequently used 
to treat children and adolescents with ADHD within a 
network meta-analysis and MTC. This comparison of 
Table 5  Effect of treatment on change from baseline in ADHD-RS-IV total score (drug—placebo)
Core Bayesian analysis: random-effects model, combined doses, excluding short-term studies, and adjusted for age and percent female
Both forced- and optimal-dose studies were included in the network. Among forced-dose studies, randomization arms included GXR 1, 2, 3, and 
4 mg/day; LDX 30, 50, and 70 mg/day; and ATX 0.5, 1.2, and 1.8 mg/kg/day. All MPH-ER studies were optimal-dose studies. MPH-IR was not 
included in the network because there were no available trials
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atomoxetine, GXR guanfacine extended release, LDX lis-
dexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate release
 Drug Mean change 95% credible interval Probability of the treatment  
being most effective among all
Probability of GXR being more effec-
tive compared with each treatment
GXR −8.68 (−10.63, −6.72) <1% –
LDX −14.98 (−17.14, −12.80) 99.96% <1%
ATX −6.88 (−8.22, −5.49) <1% 93.91%
MPH-ER −9.33 (−11.63, −7.04) <1% 33.04%
Table 6  Odds ratios and relative risks for treatment response, as defined by a CGI-I score of 1 or 2 (drug versus placebo)
Core Bayesian analysis: random-effects model, combined doses, excluding short-term studies, and adjusted for age and percent female
Both forced- and optimal-dose studies were included in the network. Among forced-dose studies, randomization arms included GXR 1, 2, 3, and 
4 mg/day; LDX 30, 50, and 70 mg/day; ATX 0.5 and 1.2 mg/kg/day; MPH-ER 20, 40, and 60 mg/day; and MPH-IR 30 mg/day. Unlike for the 
ADHD-RS-IV outcome, MPH-IR trial data with CGI-I scores were available. Hence, MPH-IR was included in the CGI-I network
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atomoxetine, CGI-I Clinical Global Impression–Improve-
ment, GXR guanfacine extended release, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylpheni-
date immediate release
a The placebo risk is the pooled risk of response (CGI-I of 1 or 2) of the placebo arms in the data. The placebo risk uncertainty is measured as 
the 95% confidence interval around this pooled placebo risk. The odds ratio was converted to a relative risk scale using the pooled placebo rate
 Drug Odds ratio 95% credible interval 
for odds ratio
Probability of the treatment being 
most effective among all (%)
Probability of GXR being more effective 
compared with each treatment (%)
GXR 3.34 (2.16, 5.22) <1 –
LDX 8.43 (4.91, 15.04) 96.21 <1
ATX 2.69 (1.52, 5.03) <1 76.13
MPH-ER 4.27 (2.47, 7.49) 3.21 25.27
MPH-IR 2.22 (1.08, 4.45) <1 81.68
Drug Relative risk of drug  
versus placebo
95% credible interval 
for relative risk
Response rate Placebo riska (95% confidence interval)
GXR 1.94 (1.59, 2.29) 0.59 0.31 (0.28, 0.34)
LDX 2.56 (2.21, 2.91) 0.79
ATX 1.77 (1.31, 2.26) 0.54
MPH-ER 2.13 (1.70, 2.54) 0.65
MPH-IR 1.62 (1.05, 2.17) 0.50
 Eur Child Adolesc Psychiatry
1 3
pharmacotherapies for children and adolescents with 
ADHD found that LDX was more effective than other 
treatments, including MPH-ER, with a clear separation 
in its 95% posterior distribution CrIs when comparing 
baseline-to-endpoint ADHD-RS-IV total score change. In 
the CGI-I comparison, LDX had a higher rate of response 
than other treatments, but the posterior 95% CrIs for 
the RR overlapped with those for MPH-ER. Among the 
non-stimulants included, GXR was more effective than 
ATX when comparing ADHD-RS-IV total score change 
and CGI-I response, although the 95% CrIs for efficacy 
measures overlapped. GXR was also shown to have a 
higher probability of being more efficacious than ATX, 
although the 95% CrIs and posterior distributions again 
Table 7  Pairwise heterogeneity assessment for core analyses
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atomoxetine, GXR guanfacine extended release, LDX lis-
dexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate release, PBO placebo
Outcome Treatments compared Number of trials I2 I2 confidence interval Q-statistic Q
p value
ADHD-RS-IV PBO, GXR 5 0.00 (0.00, 0.51) 1.68 0.79
PBO, LDX 3 0.94 (0.86, 0.98) 34.39 <0.01
PBO, ATX 11 0.17 (0.00, 0.57) 12.01 0.28
PBO, MPH-ER 2 0.57 – 2.32 0.13
ATX, MPH-ER 2 0.32 – 1.48 0.22
CGI-I PBO, GXR 5 0.36 (0.00, 0.76) 6.22 0.18
PBO, LDX 2 0.94 – 16.86 <0.01
PBO, ATX 2 0.86 – 7.07 0.01
PBO, MPH-ER 3 0.39 (0.00, 0.81) 3.27 0.20
PBO, MPH-IR 2 0.00 – 0.27 0.60
MPH-ER, MPH-IR 3 0.41 (0.00, 0.82) 3.38 0.18
Table 8  Odds ratios and relative risks for all-cause discontinuation (drug versus placebo)
Core Bayesian analysis: random-effects model, combined doses, excluding short-term studies, and adjusted for age and percent female
Both forced- and optimal-dose studies were included in the network. Among forced-dose studies, randomization arms included GXR 1, 2, 3, and 
4 mg/day; LDX 30, 50, and 70 mg/day; ATX 0.5, 1.2, and 1.8 mg/kg/day; MPH-IR 0.4 and 0.8 mg/kg/day; and MPH-ER 18, 20, and 36 mg/day. 
Unlike for the ADHD-RS-IV outcome, MPH-IR trial data with all-cause discontinuation rates were available. Hence, MPH-IR was included in 
the all-cause discontinuation network
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atomoxetine, GXR guanfacine extended release, LDX lis-
dexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate release
a The placebo risk is the pooled risk of discontinuation of the placebo arms in the data. The placebo risk uncertainty is measured as the 95% 
confidence interval around this pooled placebo risk. The odds ratio was converted to a relative risk scale using the pooled placebo rate
 Drug Odds ratio 95% credible interval 
for odds ratio
Probability of the treatment being least 
likely to be discontinued among all
Probability of GXR being less likely 
to be discontinued compared with each 
treatment
GXR 0.82 (0.58, 1.18) <1% –
LDX 0.58 (0.38, 0.88) 3.41% 8.75%
ATX 0.83 (0.63, 1.11) <1% 50.98%
MPH-ER 0.43 (0.31, 0.62) 19.25% <1%
MPH-IR 0.35 (0.19, 0.61) 77.23% <1%
Drug Relative risk of drug 
versus placebo
95% credible interval 
for relative risk
Response rate Placebo riska (95% confidence interval)
GXR 0.87 (0.66, 1.12) 0.25 0.28 (0.26, 0.30)
LDX 0.66 (0.46, 0.91) 0.19
ATX 0.88 (0.71, 1.08) 0.25
MPH-ER 0.52 (0.38, 0.69) 0.15
MPH-IR 0.44 (0.25, 0.69) 0.12
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overlapped. MPH-ER demonstrated higher efficacy than 
GXR on the ADHD-RS-IV and CGI-I measures, but 95% 
CrIs and posterior distributions showed overlap between 
the two treatments. This indicates that the level of evi-
dence on the efficacy of the studied treatments for these 
outcomes may approach level 1a [66]. In the core safety 
assessments, GXR and ATX appeared similar in the eval-
uation of all-cause discontinuation, but ATX had a lower 
RR of AE-related discontinuation, although the 95% CrIs 
and posterior distributions overlapped. While this study 
focused on efficacy and safety, a risk–benefit assessment 
would be a useful consideration in deciding how these 
results may be applied in real-world practice, and this 
could be a useful topic for further research.
Although we found that GXR had higher rates of 
CGI-I response than MPH-IR, all three MPH-IR stud-
ies included in the CGI-I efficacy MTC were published 
during or before 2006 [26, 59, 62]. The timing of these 
studies might have influenced their design or conduct, 
and hence modified the relative rates of CGI-I response 
for MPH-IR versus placebo, explaining the higher CGI-I 
response rates of GXR in comparison with MPH-IR. 
The timing of the studies might also have influenced 
their choice of outcome (all three studies used the Inat-
tention/Overactivity With Aggression Conners’ Rating 
Scale or SNAP-IV, rather than ADHD-RS-IV), leading to 
exclusion of MPH-IR as a comparator in the ADHD-RS-
IV network for efficacy analysis due to a lack of data.
Heterogeneity in the evidence network for the efficacy 
analyses was assessed using methods recommended by 
NICE guidelines [20]. The DIC of the fixed and random-
effects models were compared; this assessment found 
that there is no statistical evidence of residual heteroge-
neity after the meta-regression adjustments. In addition, 
for completeness, following the NICE guidelines, het-
erogeneity was also assessed using I2 and Cochran’s Q 
test for each feasible pair of medications without regard 
to the meta-regression adjustments. These two tests 
showed no statistically significant evidence of heteroge-
neity for ADHD-RS-IV change from baseline and CGI-I 
for pairwise comparisons of GXR versus placebo, ATX 
versus placebo, MPH-ER versus placebo, MPH-ER ver-
sus ATX, MPH-IR versus placebo, and MPH-ER versus 
MPH-IR, indicating that variability in effect-size esti-
mates for these comparisons was due to sampling error 
within studies, rather than heterogeneity. Statistically 
significant heterogeneity was detected for LDX versus 
placebo for ADHD-RS-IV change from baseline and for 
LDX versus placebo and ATX versus placebo for CGI-
I. This indicates that the treatment effect may differ in 
magnitude across trials for the LDX versus placebo and 
ATX versus placebo pairwise comparisons without the 
Table 9  Odds ratios and relative risks for discontinuation due to AEs (drug versus placebo)
Core Bayesian analysis: random-effects model, combined doses, excluding short-term studies, and adjusted for age and percent female
Both forced- and optimal-dose studies were included in the network. Among forced-dose studies, randomization arms included GXR 1, 2, 3, and 
4 mg/day; LDX 30, 50, and 70 mg/day; ATX 0.5, 1.2, and 1.8 mg/kg/day; and MPH-ER 18, 20, and 36 mg/day. Unlike for the ADHD-RS-IV 
outcome, MPH-IR trial data with AE-related discontinuation rates were available. Hence, MPH-IR was included in the AE-related discontinua-
tion network. All MPH-IR studies were optimal-dose studies
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, AE adverse event, ATX atomoxetine, GXR guanfacine extended 
release, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate release
a The placebo risk is the pooled risk of discontinuation of the placebo arms in the data. The placebo risk uncertainty is measured as the 95% 
confidence interval around this pooled placebo risk. The odds ratio was converted to a relative risk scale using the pooled placebo rate
 Drug Odds ratio 95% credible interval  
for odds ratio
Probability of the treatment 
being least likely to be discon-
tinued among all
Probability of GXR being less 
likely to be discontinued com-
pared with each treatment
GXR 4.50 (2.14, 10.31) <1% –
LDX 2.95 (1.21, 7.59) 1.67% 22.55%
ATX 2.35 (1.27, 4.37) <1% 7.74%
MPH-ER 1.29 (0.59, 2.77) 33.50% 1.05%
MPH-IR 1.02 (0.32, 3.18) 63.85% 1.89%
Drug Relative risk of  
drug versus placebo
95% credible interval  
for relative risk
Response rate Placebo riska (95% confidence 
interval)
GXR 4.49 (2.10, 8.81) 0.08 0.02 (0.01, 0.02)
LDX 3.11 (1.20, 6.76) 0.06
ATX 2.39 (1.26, 4.11) 0.04
MPH-ER 1.38 (0.60, 2.68) 0.03
MPH-IR 1.20 (0.32, 3.06) 0.02
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meta-regression adjustments. Overall, the heterogeneity 
assessment found no heterogeneity in the evidence net-
work for the efficacy analyses when accounting for meta-
regression adjustments.
The findings from the core analyses that LDX was the 
most efficacious treatment and MPH-IR the most toler-
able were confirmed by all of the sensitivity analyses 
across efficacy and safety outcomes. Among non-stim-
ulants, GXR was more efficacious than ATX in all core 
and sensitivity analyses for the ADHD-RS-IV and CGI-I 
outcomes. Core and sensitivity analyses for AE-related 
discontinuation were consistent in showing that ATX had 
higher tolerability than GXR. While the core analysis for 
all-cause discontinuation found ATX to have the highest 
RR of discontinuation, followed by GXR, the three sen-
sitivity analyses all found GXR to have the highest RR, 
followed by ATX. There was a large overlap in the CrIs 
for both safety outcomes. These differences are poten-
tially related to differences in the two drugs’ mechanism 
of action: GXR is a selective α-2 adrenergic agonist, 
while ATX is a norepinephrine reuptake inhibitor.
A systematic literature review and meta-analysis of stud-
ies comparing GXR and placebo was conducted recently 
by Ruggiero et al. [7], but the current study has important 
differences. Ruggiero et al. performed direct comparisons 
solely on GXR (by pooling GXR and placebo arms) and 
did not supplement the information using clinical study 
reports; in contrast, the current study included a broader 
selection of pharmacotherapies and considered both direct 
and indirect evidence, and used information from clini-
cal study reports to supplement the primary publication, 
which allowed inclusion of the ADHD-RS-IV change from 
baseline from Biederman et al. [28] and Sallee et al. [30]. 
In these cases, the clinical study reports were used to pre-
vent any potential bias resulting from exclusion of this 
information. We excluded the following studies that were 
included in the publication by Ruggiero et al. [7]: Scahill 
et al. [67] only included subjects from a specialty tic dis-
order clinic; Connor et al. [68] required all subjects to have 
oppositional symptoms; and trial NCT01081132 did not 
have any publications. This allowed our study to be more 
homogenous and to focus solely on ADHD, whereas Rug-
giero et al. [7] included two common comorbidities. The 
present study assessed somewhat different outcomes than 
Ruggiero et al. [7], which assessed CGI-I response, rates of 
patients with at least one AE, and rates of individual AEs. 
Nevertheless, our conclusions were generally consistent 
with those of Ruggiero et al. [7] in the common analysis of 
CGI-I response. In their CGI-I analysis, Ruggiero et al. [7] 
found that GXR was associated with a greater proportion 
of patients with CGI-I response, with a pooled odds ratio 
(OR) of 3.18 (95% CI 2.44, 4.13), with between-study het-
erogeneity accounting for 26% of the difference. The core 
analysis of CGI-I in the present study found a comparable 
OR of 3.34 (95% CrI 2.16, 5.22) for GXR.
A recent systematic review and meta-analysis, by Stuhec 
and colleagues [69], included LDX, MPH, and bupropion, 
but not GXR. The study incorporated data from 28 trials 
using the random-effects model of derSimonian and Laird 
[70] and compared each drug with placebo; it did not incor-
porate MTCs. ORs for all-cause discontinuation reported 
by Stuhec et al. [69] are comparable with those in this 
study for ATX (OR: 0.91 [95% CI 0.66, 1.24] in Stuhec 
et al. [68] versus 0.83 [95% CrI 0.63, 1.11]) and LDX (OR: 
0.6 [95% CI 0.22, 1.65] versus 0.58 [95% CrI 0.38, 0.88]). 
Other outcomes and treatments were reported in ways 
directly comparable with this study. Roskell et al. [71] is 
another recent systematic literature review and indirect 
comparison. Unlike the preceding two comparisons and the 
present one, Roskell et al. [71] focused on comparing LDX 
with MPH and ATX. The study identified 32 trials. While 
the results were not directly comparable with those of the 
present study, which compares the treatments with placebo 
rather than LDX, the approximate RR for CGI-I response 
was 0.65 for ATX versus LDX in Roskell et al. [71], com-
pared with 0.69 in the present study (obtained as the ratio 
of the RRs for ATX versus placebo and LDX versus pla-
cebo). The corresponding RR comparison (Roskell et al. 
[71] versus present study) is 1.33 versus 1.33 for all-cause 
discontinuation and 0.58 versus 0.77 for AE-related discon-
tinuation. Thus, the findings of the Roskell et al. study are 
consistent with those of the present study.
Furthermore, pooled results of direct and indirect evi-
dence with respect to the non-stimulants GXR and ATX 
from this MTC were also consistent with previously pub-
lished direct comparisons. Direct evidence was available 
from Hervas et al. [41], in which a comparison between 
GXR and the ATX reference arm was pre-specified; this 
comparison was carried out for health technology assess-
ment purposes. That article reported ADHD-RS-IV total 
score changes from baseline (standard deviation) in the 
placebo, GXR, and ATX arms of −15.0 (13.07), −23.9 
(12.41), and −18.6 (11.91), respectively. There was a sig-
nificant difference between GXR and ATX when analysing 
the difference in mean change from baseline in ADHD-RS-
IV total score at the trial endpoint (treatment effect: −5.1 
[95% CI −8.2, −2.0], p = 0.001) favoring GXR (second-
ary analyses, not controlled for multiplicity). The results 
from that trial are broadly consistent with this MTC, in that 
GXR exhibited a larger treatment effect than ATX. In addi-
tion, Hervas et al. [41] reported the proportion of patients 
achieving a CGI-I response in each of three arms: placebo, 
GXR, and ATX. The percentages in these arms were 44.1, 
67.9, and 56.3%, respectively. The raw RR of CGI-I com-
pared with placebo, based on these proportions, was 1.54 
for GXR and 1.28 for ATX. The ratio of RRs (RR for GXR/
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RR for ATX) was larger in the Hervas et al. study [41] than 
in this MTC (1.21 versus 1.09). As in this MTC, GXR 
exhibited a numerically greater treatment effect than ATX 
in the study by Hervas et al. [41]. Lastly, these results are 
also supportive of published indirect comparisons of ATX 
versus GXR [5, 72]. In the study by Signorovitch et al. 
[72], GXR was found to be associated with a significantly 
greater mean reduction in the CPRS-short form opposi-
tional subscale score compared with ATX when comparing 
matched populations (GXR: −5.0 [95% CI −6.6, −3.4]; 
ATX: −2.4 [95% CI −3.7, −1.1], p = 0.01). In the study 
by Sikirica et al. [5], GXR was found to be associated with 
a significantly greater mean reduction in ADHD-RS-IV 
total score compared with ATX when comparing matched 
populations (−7.0 [standard error: 2.2], p < 0.01). Signifi-
cantly greater reductions with GXR over ATX were also 
found in scores on the ADHD-RS-IV hyperactivity/impul-
sivity (−3.8 [standard error: 1.2], p < 0.01) and inattention 
(−3.2 [standard error: 1.3], p < 0.05) subscales.
Regarding safety results, we found that all of the treat-
ments were generally similar in their all-cause and AE-
related discontinuation rates, with no clear differences 
between treatments. There seemed to be a slightly larger 
probability of more discontinuations in the GXR group due 
to AEs relative to other treatments. However, further study 
is needed to confirm if this is a real finding or one related to 
the fact that safety is often measured as a proportion rather 
than a continuous measure, which further limits the anal-
ysis and interpretability as this effectively gives a smaller 
number of observations from these RCTs for safety than 
for efficacy analyses.
There were several limitations to this study due to data 
constraints. The analyses adjusted for baseline age, sex, 
and disease severity but, as is common to meta-analyses, 
differences that were not uniformly reported across the 
trials (e.g., prior treatments, comorbidities) and heteroge-
neity due to unobserved variables could not be captured. 
This may have led to uncontrolled residual confound-
ing. Matching-adjusted indirect comparisons [5, 72] 
can increase the validity of comparison when individual 
patient-level data are available for some of the trials. Het-
erogeneity could not be assessed in this MTC by compar-
ing placebo effects because the methodology, as is com-
mon in MTCs, does not compare different placebo arms. 
However, an assessment comparing the DIC between 
the fixed- and random-effects analyses indicated that 
heterogeneity was not statistically significant in the evi-
dence networks for the efficacy outcomes. This analysis 
included trials of 3–16 weeks duration. These cutoffs were 
chosen to allow sufficient time for the effects of different 
treatments to take effect while still retaining comparabil-
ity of trials. The analysis did not adjust for differences in 
trial length, under the assumption that trial durations were 
chosen by investigators according to each drug’s duration 
of action. However, variation in trial durations might have 
had unknown effects on the outcomes of this analysis. For 
example, adverse effects may take longer to occur with 
some drugs than with others [73]. In such cases, the drugs 
whose effects manifest earlier will have an unfair disad-
vantage in this type of study, due to the large number of 
studies of relatively short duration. However, the findings 
in sensitivity analyses including shorter duration studies 
were consistent with those in the core analyses. Sepa-
rate comparisons for stimulant-naïve and stimulant-failed 
populations were not feasible due to data limitations. Fur-
ther research is needed to identify subgroups of patients 
who might receive greater benefit from specific treatments 
once more indirect or preferably direct head-to-head evi-
dence is available. For example, prior treatment might 
indicate refractory patients in whom a reduced treatment 
effect is likely. Furthermore, analyses of discontinuation 
rates might not be directly interpretable as indications of 
drug safety, as discontinuation can be much more directly 
influenced by trial protocol specifications than efficacy 
measurements. Different trials might not be consistent in 
their discontinuation specifications—in particular, AE-
related discontinuation rates did not account for different 
types of AEs. AE-related discontinuation also had limited 
sample sizes for MPH-IR. This study relied on assess-
ments of each trial to account for patients who dropped 
out for any reason (including discontinuation of study 
medication); for example, trials in which patients dropped 
out were not excluded. This study used the Bayesian 
method, as suggested in the NICE Decision Support Unit 
Technical Support Documents; however, the results from 
this method might depend on the choice of prior distribu-
tions for the models’ parameters. Non-informative priors 
were chosen so that the priors would not influence the 
results, and sensitivity analyses indicated that the results 
were stable with respect to priors. This study also focused 
on each of the included treatments as monotherapy, and 
its findings are not generalizable to combination-therapy 
settings. In addition, this study treated all versions of a 
particular drug, for example MPH-ER, as the same, while 
in reality they might have different effects. It also treated 
all doses of any specific drug as the same; thus, the effi-
cacy and safety findings apply to a population in which 
proportions of patients receive different doses of each 
drug. The study also did not distinguish between studies 
that reported doses using different units or distinguish 
between those with and without a titration period, due to 
the sparsity of data within these categories. The inclusion 
of open-label trials may have led to biases favoring ATX 
[69]. Another difference that was not specifically assessed 
within the scope of the study was whether the trials were 
laboratory trials. For 4 RCTs, the MPH duration of action 
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was not clearly specified; studies were classified as MPH-
ER or -IR based on dosing details provided in the corre-
sponding publications. Because the classification into ER 
or IR is not provided in the publications, there is potential 
for inaccuracies in the classification for these 4 studies. 
A misclassification in these studies is unlikely to have 
much impact on the findings of the meta-analysis, how-
ever, because the classification was performed for only 4 
out of 20 MPH studies, and the studies had small to mod-
erate sample sizes. In a sensitivity analysis changing the 
imputed classification of MPH in the largest of these 4 
studies, there was little change in the results, showing that 
the findings are robust to this imputation. Finally, lack of 
data limited the treatments that could be included in the 
MTC, as well as the outcome measures that could be used 
for the comparisons. In particular, d-AMPH, CIR, and 
GIR could not be included even though these drugs have 
similarities to GXR, as they did not form a connected net-
work with GXR through any of the publications identified.
In summary, based on published evidence, both direct 
and indirect, this study found that LDX had greater effi-
cacy than GXR, ATX, and MPH in reducing symptoms 
in children and adolescents with ADHD, with no over-
lap in CrIs on the ADHD-RS-IV. The probability was 
also higher in the overall impression of improvement, 
although there was overlap in CrIs. Safety, as meas-
ured by all-cause and AE-related discontinuations, was 
slightly better for MPH relative to other therapies, but 
the sample sizes were relatively low and statistical uncer-
tainty was high for this outcome. Further study with an 
updated network is warranted if additional direct or indi-
rect evidence becomes available.
Acknowledgements This research was funded by Shire Develop-
ment, LLC. The authors wish to acknowledge the contributions of 
Zhanna Zhanabekova, Ying Daisy Zhuo, and Emi Terasawa in con-
ducting the literature review and analyses included in this manu-
script. Editorial assistance in formatting, proofreading, and copyedit-
ing the manuscript, and coordination and collation of comments was 
provided by Caudex, funded by Shire International GmbH. Antonia 
Panayi from Shire also reviewed the manuscript for scientific accu-
racy. Although employees of Shire were involved in the design, col-
lection, analysis, interpretation, and fact checking of information, the 
content of this manuscript, the interpretation of the data, and the deci-
sion to submit the manuscript for publication in European Child & 
Adolescent Psychiatry was made by the authors independently.
Compliance with ethical standards 
Ethical standards The manuscript does not contain clinical studies or 
patient data that have not been published previously.
Conflict of interest Alain Joseph is an employee of Shire. Rajeev 
Ayyagari, and Jipan Xie are employees of Analysis Group, Inc., which 
received consulting fees from Shire for this research. Sean Cai and 
Meng Xie are former employees of Analysis Group, Inc. Michael Huss 
is a member of advisory boards and has spoken at educational events 
for Actelion, Eli Lilly, Engelhard Arzneimittel, Janssen Cilag, Medice, 
Novartis, and Shire, and has received consultation fees from Engelhard 
Arzneimittel and Steiner Arzneimittel. Vanja Sikirica was an employee 
of Shire at the time of the study.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. National Collaborating Centre for Mental Health (2009) Atten-
tion deficit hyperactivity disorder: diagnosis and management of 
ADHD in children, young people and adults. British Psychologi-
cal Society (UK), Chicago
 2. Arnold LE (2000) Methylphenidate versus amphetamine: com-
parative review. J Atten Disord 3:200–211
 3. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson 
CL, Jacobsen SJ (2006) Long-term stimulant medication treat-
ment of attention-deficit/hyperactivity disorder: results from a 
population-based study. J Dev Behav Pediatr 27:1–10
 4. Biederman J, Arnsten AF, Faraone SV, Doyle AE, Spencer TJ, 
Wilens TE, Weiss MD, Safren SA, Culpepper L (2006) New 
developments in the treatment of ADHD. J Clin Psychiatry 
67:148–159
 5. Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman 
R, Hodgkins P, Lu M, Xie J, Wu EQ (2013) Comparative effi-
cacy of guanfacine extended release versus atomoxetine for the 
treatment of attention-deficit/hyperactivity disorder in children 
and adolescents: applying matching-adjusted indirect compari-
son methodology. CNS Drugs 27:943–953
 6. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, 
Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-
Barke E, Steinhausen HC (2004) European clinical guidelines 
for hyperkinetic disorder–first upgrade. Eur Child Adolesc Psy-
chiatry 13:i7–i30
 7. Ruggiero S, Clavenna A, Reale L, Capuano A, Rossi F, Bonati 
M (2014) Guanfacine for attention deficit and hyperactivity dis-
order in pediatrics: a systematic review and meta-analysis. Eur 
Neuropsychopharmacol 24:1578–1590
 8. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD 
Rating Scale-IV: Checklists, norms, and clinical interpretation. 
Guilford Press, New York
 9. Guy W (1976) ECDEU Assessment Manual for Psychopharma-
cology–Revised. (DHEW Publ No ADM 76,338). US Depart-
ment of Health, Education, and Welfare, Public Health Service, 
Alcohol, Drug Abuse, and Mental Health Administration, NIMH 
Psychopharmacology Research Branch, Division of Extramural 
Research Programs, Rockville, pp 218–222
 10. Conners CK, Sitarenios G, Parker JD, Epstein JN (1998) Revi-
sion and restandardization of the Conners’ Teacher Rating Scale 
(CPRT-R). J Abnorm Child Psychol 26:279–291
 11. Swanson JM (1992) School-based assessments and interventions 
for ADD students. KC Publishing, Irvine
 12. National Institute for Health and Care Excellence (2012) 
Single technology appraisal (STA): specification for manu-
facturer/sponsor submission of evidence. https://www.nice. 
org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/
howwework/devnicetech/specificationformanufacturersponsor-
submissionofevidence.jsp. Accessed 15 June 2015
Eur Child Adolesc Psychiatry 
1 3
 13. Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, 
Paulden M, Conti S, Welton NJ, Abrams KR, Bujkiewicz S, 
Spiegelhalter D, Sutton AJ (2011) How valuable are multiple 
treatment comparison methods in evidence-based health-care 
evaluation? Value Health 14:371–380
 14. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawk-
ins N, Lee K, Boersma C, Annemans L, Cappelleri JC (2011) 
Interpreting indirect treatment comparisons and network meta-
analysis for health-care decision making: report of the ISPOR 
Task Force on Indirect Treatment Comparisons Good Research 
Practices: part 1. Value Health 14:417–428
 15. National Institute for Health and Care Excellence (2014). A 
general linear modelling framework for pair-wise and network 
meta-analysis of randomised controlled trials. Decision Sup-
port Unit Technical Support Document. http://www.nicedsu.
org.uk/TSD2%20General%20meta%20analysis%20cor-
rected%2015April2014.pdf. Accessed 15 June 2015
 16. Geweke J (1991) Evaluating the accuracy of sampling-based 
approaches to the calculation of posterior moments. Federal 
Reserve Bank of Minneapolis, Research Department Staff 
Report 148. https://www.minneapolisfed.org/research/sr/sr148.
pdf. Accessed 15 June 2015
 17. Heidelberger P, Welch PD (1981) A spectral method for con-
fidence interval generation and run length control in simula-
tions. Commun ACM 24:233–245
 18. Heidelberger P, Welch PD (1983) Simulation run length control 
in the presence of an initial transient. Oper Res 31:1109–1144
 19. Schruben LW (1982) Detecting initialization bias in simulation 
output. Oper Res 30:569–590
 20. National Institute for Health and Care Excellence (2011). Het-
erogeneity: subgroups, meta-regression, bias and bias-adjust-
ment. Decision Support Unit Technical Support Document. 
http://www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20
report.08.05.12.pdf. Accessed 5 September 2016
 21. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, 
Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey 
CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, 
Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM (2006) 
Multisite controlled study of OROS methylphenidate in the treat-
ment of adolescents with attention-deficit/hyperactivity disorder. 
Arch Pediatr Adolesc Med 160:82–90
 22. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crock-
ett RS (2005) Outcomes of OROS methylphenidate compared 
with atomoxetine in children with ADHD: a multicenter, rand-
omized prospective study. Adv Ther 22:498–512
 23. Greenhill LL, Findling RL, Swanson JM, ADHD Study Group 
(2002) A double-blind, placebo-controlled study of modified-
release methylphenidate in children with attention-deficit/
hyperactivity disorder. Pediatrics 109:E39
 24. Pliszka SR, Browne RG, Olvera RL, Wynne SK (2000) A 
double-blind, placebo-controlled study of Adderall and meth-
ylphenidate in the treatment of attention-deficit/hyperactivity 
disorder. J Am Acad Child Adolesc Psychiatry 39:619–626
 25. Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, 
Edson K, Karlsson G, Pohlmann H, Wigal S (2003) Efficacy 
and safety of Ritalin LA, a new, once daily, extended-release 
dosage form of methylphenidate, in children with attention 
deficit hyperactivity disorder. Paediatr Drugs 5:833–841
 26. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, 
McDowell M (2006) Comparison of the clinical efficacy of 
twice-daily Ritalin and once-daily Equasym XL with placebo 
in children with attention deficit/hyperactivity disorder. Eur 
Child Adolesc Psychiatry 15:450–459
 27. Ialongo N, López M, Horn WF, Pascoe JM, Greenberg G 
(1994) Effects of psychostimulant medication on self-per-
ceptions of competence, control, and mood in children with 
attention deficit hyperactivity disorder. J Clin Child Psychol 
23:161–173
 28. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL 
(2007) Efficacy and tolerability of lisdexamfetamine dimesylate 
(NRP-104) in children with attention-deficit/hyperactivity disor-
der: a phase III, multicenter, randomized, double-blind, forced-
dose, parallel-group study. Clin Ther 29:450–463
 29. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, 
Lyne A, Scherer N, SPD503 Study Group (2008) A randomized, 
double-blind, placebo-controlled study of guanfacine extended 
release in children and adolescents with attention-deficit/hyper-
activity disorder. Pediatrics 121:e73–e84
 30. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman 
J, SPD503 Study Group (2009) Guanfacine extended release in 
children and adolescents with attention-deficit/hyperactivity dis-
order: a placebo-controlled trial. J Am Acad Child Adolesc Psy-
chiatry 48:155–165
 31. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratoch-
vil CJ, Conners CK, Potter WZ (2002) Results from 2 proof-of-
concept, placebo-controlled studies of atomoxetine in children 
with attention-deficit/hyperactivity disorder. J Clin Psychiatry 
63:1140–1147
 32. Block SL, Kelsey D, Coury D, Lewis D, Quintana H, Sutton V, 
Schuh K, Allen AJ, Sumner C (2009) Once-daily atomoxetine for 
treating pediatric attention-deficit/hyperactivity disorder: compari-
son of morning and evening dosing. Clin Pediatr (Phila) 48:723–733
 33. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson 
M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires 
L (2013) European, randomized, phase 3 study of lisdexamfeta-
mine dimesylate in children and adolescents with attention-deficit/
hyperactivity disorder. Eur Neuropsychopharmacol 23:1208–1218
 34. Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, 
Lehmann M, Lehmkuhl G, Wehmeier PM (2011) Atomoxetine 
versus placebo in children and adolescents with attention-deficit/
hyperactivity disorder and comorbid oppositional defiant disor-
der: a double-blind, randomized, multicenter trial in Germany. J 
Child Adolesc Psychopharmacol 21:97–110
 35. Dittmann R, Cardo E, Nagy P, Anderson CS, Bloomfield R, 
Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D 
(2013) Efficacy and safety of lisdexamfetamine dimesylate and 
atomoxetine in the treatment of attention-deficit/hyperactivity 
disorder: a head-to-head, randomized, double-blind, phase IIIb 
study. CNS Drugs 27:1081–1092
 36. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, 
Arnold LE, Pratt RD (2008) A randomized, double-blind, pla-
cebo-controlled, parallel-group study of methylphenidate trans-
dermal system in pediatric patients with attention-deficit/hyper-
activity disorder. J Clin Psychiatry 69:149–159
 37. Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Fer-
reira-Cornwell MC, Squires L (2011) Efficacy and safety of lisdex-
amfetamine dimesylate in adolescents with attention-deficit/hyper-
activity disorder. J Am Acad Child Adolesc Psychiatry 50:395–405
 38. Garg J, Arun P, Chavan BS (2014) Comparative short term effi-
cacy and tolerability of methylphenidate and atomoxetine in 
attention deficit hyperactivity disorder. Indian Pediatr 51:550–554
 39. Gau SS, Shen HY, Soong WT, Gau CS (2006) An open-label, 
randomized, active-controlled equivalent trial of osmotic release 
oral system methylphenidate in children with attention-deficit/
hyperactivity disorder in Taiwan. J Child Adolesc Psychophar-
macol 16:441–455
 40. Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang 
CY, Tseng WL, Allen AJ, Lee P (2007) A randomized, double-
blind, placebo-controlled clinical trial on once-daily atomox-
etine in Taiwanese children and adolescents with attention-def-
icit/hyperactivity disorder. J Child Adolesc Psychopharmacol 
17:447–460
 Eur Child Adolesc Psychiatry
1 3
 41. Hervas A, Huss M, Johnson M, McNicholas F, van Stralen 
J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson 
B (2014) Efficacy and safety of extended-release guanfacine 
hydrochloride in children and adolescents with attention-deficit/
hyperactivity disorder: a randomized, controlled, Phase III trial. 
Eur Neuropsychopharmacol 24:1861–1872
 42. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Say-
lor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen 
AJ (2004) Once-daily atomoxetine treatment for children with 
attention-deficit/hyperactivity disorder, including an assessment 
of evening and morning behavior: a double-blind, placebo-con-
trolled trial. Pediatrics 114:e1–e8
 43. Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne 
A, Wigal SB, Roth T (2011) Psychomotor functioning and alert-
ness with guanfacine extended release in subjects with attention-
deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 
21:111–120
 44. López F, Silva R, Pestreich L, Muniz R (2003) Comparative effi-
cacy of two once daily methylphenidate formulations (Ritalin 
LA and Concerta) and placebo in children with attention defi-
cit hyperactivity disorder across the school day. Paediatr Drugs 
5:545–555
 45. Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Sol-
datenkova VO, Bardenstein LM, Kozlova IA, Neznanov NG, 
Maslova OI, Petrukhin AS, Sukchotina NK, Zykov VP (2010) 
Atomoxetine in children and adolescents with attention-deficit/
hyperactivity disorder: a 6-week, randomized, placebo-con-
trolled, double-blind trial in Russia. Eur Child Adolesc Psychi-
atry 19:57–66
 46. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sal-
lee FR, Spencer T, Atomoxetine ADHD Study Group (2001) 
Atomoxetine in the treatment of children and adolescents with 
attention-deficit/hyperactivity disorder: a randomized, placebo-
controlled, dose-response study. Pediatrics 108:E83
 47. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil 
C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey 
D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomox-
etine treatment for children and adolescents with attention deficit 
hyperactivity disorder: a randomized, placebo-controlled study. 
Am J Psychiatry 159:1896–1901
 48. Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, 
Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Esco-
bar R (2009) Evaluation of atomoxetine for first-line treatment 
of newly diagnosed, treatment-naive children and adolescents 
with attention deficit/hyperactivity disorder. Curr Med Res Opin 
25:2745–2754
 49. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, 
Moore RJ, Michelson D, Atomoxetine/Methylphenidate Com-
parative Study Group (2008) Atomoxetine and osmotically 
released methylphenidate for the treatment of attention defi-
cit hyperactivity disorder: acute comparison and differential 
response. Am J Psychiatry 165:721–730
 50. Newcorn JH, Stein MA, Childress AC, Youcha S, White C, 
Enright G, Rubin J (2013) Randomized, double-blind trial of 
guanfacine extended release in children with attention-deficit/
hyperactivity disorder: morning or evening administration. J Am 
Acad Child Adolesc Psychiatry 52:921–930
 51. Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss 
WB, McDermott MP (2008) Clonidine for attention-deficit/
hyperactivity disorder: I. efficacy and tolerability outcomes. J 
Am Acad Child Adolesc Psychiatry 47:180–188
 52. Shang CY, Pan YL, Lin HY, Huang LW, Gau SS (2015) An open-
label, randomized trial of methylphenidate and atomoxetine 
treatment in children with attention-deficit/hyperactivity disor-
der. J Child Adolesc Psychopharmacol 25:566–573
 53. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE 
(2006) A randomized, controlled effectiveness trial of OROS-
methylphenidate compared to usual care with immediate-release 
methylphenidate in attention deficit-hyperactivity disorder. Can J 
Clin Pharmacol 13:e50–e62
 54. Su Y, Yang L, Stein MA, Cao Q, Wang Y (2016) Osmotic release 
oral system methylphenidate versus atomoxetine for the treat-
ment of attention-deficit/hyperactivity disorder in Chinese youth: 
8-week comparative efficacy and 1-year follow-up. J Child Ado-
lesc Psychopharmacol 26:362–371
 55. Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, 
Kambayashi Y, Koeda T, Oki J, Saito K, Takeshita K, Allen AJ 
(2009) A randomized, double-blind, placebo-controlled study of 
atomoxetine in Japanese children and adolescents with attention-
deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 
19:341–350
 56. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, 
Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine 
LR (2007) Atomoxetine versus methylphenidate in paediatric 
outpatients with attention deficit hyperactivity disorder: a ran-
domized, double-blind comparison trial. Aust NZ J Psychiatry 
41:222–230
 57. Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schnei-
der-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T 
(2012) Does atomoxetine improve executive function, inhibitory 
control, and hyperactivity? Results from a placebo-controlled 
trial using quantitative measurement technology. J Clin Psychop-
harmacol 32:653–660
 58. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, 
Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A 
randomized, placebo-controlled study of once-daily atomoxetine 
in the school setting in children with ADHD. J Am Acad Child 
Adolesc Psychiatry 44:647–655
 59. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, 
Zeldis JB, Conners CK (2004) A double-blind, placebo-con-
trolled trial of dexmethylphenidate hydrochloride and d, l-threo-
methylphenidate hydrochloride in children with attention-deficit/
hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 
43:1406–1414
 60. Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, 
Hall CM, Olson E, Robieson WZ, Garimella TS, Abi-Saab WM, 
Apostol G, Saltarelli MD (2011) Safety and efficacy of ABT-089 
in pediatric attention-deficit/hyperactivity disorder: results from 
two randomized placebo-controlled clinical trials. J Am Acad 
Child Adolesc Psychiatry 50(73–84):e71
 61. Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloom-
field R, Cutler AJ (2015) A randomized, placebo-controlled trial 
of guanfacine extended release in adolescents with attention-def-
icit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 
54:916–925
 62. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, 
Palumbo D, Atkins M, McBurnett K, Bukstein O, August G 
(2001) Randomized, controlled trial of OROS methylphenidate 
once a day in children with attention-deficit/hyperactivity disor-
der. Pediatrics 108:883–892
 63. Shaffer D, Fisher P, Dulcan MK, Davies M, Piacentini J, 
Schwab-Stone ME, Lahey BB, Bourdon K, Jensen PS, Bird 
HR, Canino G, Regier DA (1996) The NIMH Diagnostic 
Interview Schedule for Children Version 2.3 (DISC-2.3): 
description, acceptability, prevalence rates, and performance 
in the MECA study. J Am Acad Child Adolesc Psychiatry 
35:865–877
 64. Huedo-Medina TB, Sánchez-Meca J, Marin-Martinez F, Botella 
J (2006) Assessing heterogeneity in meta-analysis: Q statistic or 
I2 index? Psychol Methods 11:193–206
Eur Child Adolesc Psychiatry 
1 3
 65. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 [updated March 2011]. 
The Cochrane Collaboration, 2011. Available from www.hand-
book.cochrane.org
 66. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B 
(1998) Oxford Centre for Evidence-based Medicine—Levels 
of Evidence (updated by Jeremy Howick, March 2009). http://
www.cebm.net/oxford-centre-evidence-based-medicine-levels-
evidence-March-2009/ Accessed 19 January 2016
 67. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shep-
herd E, Arnsten AF, Cohen DJ, Leckman JF (2001) A placebo-
controlled study of guanfacine in the treatment of children with 
tic disorders and attention deficit hyperactivity disorder. Am J 
Psychiatry 158:1067–1074
 68. Connor DF, Findling RL, Kollins SH, Sallee F, Lopez FA, Lyne 
A, Tremblay G (2010) Effects of guanfacine extended release on 
oppositional symptoms in children aged 6–12 years with atten-
tion-deficit hyperactivity disorder and oppositional symptoms: a 
randomized, double-blind, placebo-controlled trial. CNS Drugs 
24:755–768
 69. Stuhec M, Munda B, Svab V, Locatelli I (2015) Comparative 
efficacy and acceptability of atomoxetine, lisdexamfetamine, 
bupropion and methylphenidate in treatment of attention deficit 
hyperactivity disorder in children and adolescents: a meta-analy-
sis with focus on bupropion. J Affect Disord 178:149–159
 70. DerSimonian R, Laird N (1983) Evaluating the effect of coach-
ing on SAT scores: a meta-analysis. Harvard Educational Review 
53:1–15
 71. Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P (2014) Sys-
tematic evidence synthesis of treatments for ADHD in children 
and adolescents: indirect treatment comparisons of lisdexamfe-
tamine with methylphenidate and atomoxetine. Curr Med Res 
Opin 30:1673–1685
 72. Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins 
PS, Wu EQ (2012) Comparative effectiveness research using 
matching-adjusted indirect comparison: an application to treat-
ment with guanfacine extended release or atomoxetine in chil-
dren with attention-deficit/hyperactivity disorder and comorbid 
oppositional defiant disorder. Pharmacoepidemiol Drug Saf 
21:130–137
 73. Banaschewski PDDT, Coghill D, Santosh P, Zuddas A, Ash-
erson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, 
Rothenberger A, Sergeant J (2006) Long-acting medications 
for the hyperkinetic disorders. Eur Child Adolesc Psychiatry 
15:476–495
